Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Rani Therapeutics Holdings (RANI) Other financing activities (2021 - 2022)

Rani Therapeutics Holdings' Other financing activities history spans 2 years, with the latest figure at $152000.0 for Q4 2022.

On a quarterly basis, Other financing activities changed N/A to $152000.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $260000.0, a N/A change, with the full-year FY2022 number at $260000.0, changed N/A from a year prior.
Other financing activities came in at $152000.0 for Q4 2022, up from $108000.0 in the prior quarter.
The five-year high for Other financing activities was $2.2 million in Q2 2021, with the low at -$1.9 million in Q3 2021.